Table 1.
Univariate and multivariate analyses of patients with UTI caused by Pseudomonas aeruginosa detected in urine samples*
| Variable | Univariate | Multivariate† | |||
|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | ||
| Age | 1.000 (0.990–1.009) | 0.944 | 1.089 (1.017–1.166) | 0.015 | |
| Sex | |||||
| Male | Reference | ||||
| Female | 0.867 (0.596–1.262) | 0.458 | |||
| Comorbidity | |||||
| Pulmonary disease | 1.365 (0.890–2.093) | 0.154 | |||
| DM | 0.753 (0.514–1.105) | 0.148 | |||
| Susceptibility to carbapenem | |||||
| CsPA | Reference | ||||
| Cns-nCPPA | 0.717 (0.395–1.300) | 0.273 | |||
| Cns-CPPA | 1.018 (0.688–1.505) | 0.931 | |||
| Carbapenem use | 2.072 (1.339–3.204) | 0.001 | 1.943 (1.163–3.248) | 0.011 | |
| Imipenem | 0.275 (0.025–3.054) | 0.293 | |||
| Meropenem | - | ||||
| Doripenem | 1.737 (0.954–3.164) | 0.071 | |||
| Ertapenem | 2.740 (1.455–5.161) | 0.001 | |||
| Laboratory finding | |||||
| Procalcitonin (ng/mL) | 0.981 (0.927–1.037) | 0.492 | |||
| CRP (mg/L) | 1.004 (1.000–1.009) | 0.042 | 1.003 (0.998–1.008) | 0.230 | |
| WBC (109/L) | 1.045 (1.001–1.091) | 0.036 | 0.996 (0.938–1.059) | 0.908 | |
| NLR | 1.029 (1.000–1.059) | 0.036 | 1.013 (0.970–1.058) | 0.557 | |
| Glucose (mg/dL) | 0.998 (0.994–1.003) | 0.466 | |||
| LD (IU/L) | 1.000 (1.000–1.001) | 0.819 | |||
*UTI was defined according to the CDC criteria [18]. Among 499 patients, 321 (64.3%) met the CDC criteria for UTI, whereas the remaining 178 (35.7%) patients were designated as a non-UTI group.
†Variables with P<0.05 in univariate analysis were included in the multivariate analysis.
Abbreviations: CDC, Centers for Disease Control and Prevention; CI, confidence interval; Cns-CPPA, carbapenem-non-susceptible and carbapenemase-producing P. aeruginosa; Cns-nCPPA, carbapenem-non-susceptible and non-carbapenemase-producing P. aeruginosa; CRP, C-reactive protein; CsPA, carbapenem-susceptible P. aeruginosa; DM, diabetes mellitus; OR, odds ratio; UTI, urinary tract infection; WBC, white blood cell; NLR, neutrophil-to-lymphocyte ratio; LD, lactate dehydrogenase.